Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is a medical device company focused on making diabetes management easier through the innovative Omnipod system. While they reported strong results in their recent quarter, the company's outlook is mixed due to lower revenue growth in the highly competitive US Type 2 market. Management is taking steps to address this issue and has plans to launch a new product in 2028, but until then, the stock may be range-bound. There are also potential risks of cybersecurity and data privacy concerns, but overall, the company's profitable international market and track record of outperformance are positive factors.

Bears say

Insulet is a leading manufacturer of the Omnipod insulin management system, with over 600,000 users worldwide. However, challenges in maintaining strong patent and trademark protections, as well as patent litigation and competition from established companies and new market entrants, could hinder the company's growth. Additionally, Insulet faces risks from market inflation and the potential for downturns in the diabetes market. While the company has a strong product offering and plans for continued growth, it may struggle in the near term due to issues with customer retention and new competition in the tubeless automated insulin delivery market.

Insulet (PODD) has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 21 analysts, Insulet (PODD) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $193.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $193.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.